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Introduction
Nonalcoholic fatty liver disease (NAFLD) is a condition defined by excessive (>5% by weight) fat accumu-
lation in the liver. As a consequence of  the obesity and diabetes epidemic, NAFLD has become the most 
common liver disorder in developed countries, with more than 100 million adults and children affected in 
the United States alone (1). Although NAFLD may progress to severe liver disease, including nonalcoholic 
steatohepatitis and cirrhosis (2, 3), the most common cause of  death in patients with the condition is ath-
erosclerotic cardiovascular disease (4).
NAFLD has a multifactorial etiology that includes a strong genetic component. The transmembrane 6 
superfamily member 2 (TM6SF2) rs58542926 variant, encoding for a glutamic acid to lysine substitution at 
position 167 of  the amino acid sequence (E167K), has been identified as one of  the most important genetic 
determinants of  hepatic fat content (5–7). This single nucleotide variant reduces expression of  the TM6SF2 
protein by 46% in liver cells (7), and its prevalence is around 7% in Caucasian populations (8). Despite 
extensive investigation, the molecular function of  TM6SF2 remains unclear. Localized on chromosome 
19, the gene is expressed mainly in the liver, small intestine, and kidney (7). It encodes a 351–amino acid 
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic lipid accumulation. The 
transmembrane 6 superfamily member 2 (TM6SF2) E167K genetic variant associates with NAFLD 
and with reduced plasma triglyceride levels in humans. However, the molecular mechanisms 
underlying these associations remain unclear. We hypothesized that TM6SF2 E167K affects hepatic 
very low-density lipoprotein (VLDL) secretion and studied the kinetics of apolipoprotein B100 
(apoB100) and triglyceride metabolism in VLDL in homozygous subjects. In 10 homozygote TM6SF2 
E167K carriers and 10 matched controls, we employed stable-isotope tracer and compartmental 
modeling techniques to determine apoB100 and triglyceride kinetics in the 2 major VLDL 
subfractions: large triglyceride-rich VLDL1 and smaller, less triglyceride-rich VLDL2. VLDL1-apoB100 
production was markedly reduced in homozygote TM6SF2 E167K carriers compared with controls. 
Likewise, VLDL1-triglyceride production was 35% lower in the TM6SF2 E167K carriers. In contrast, 
the direct production rates for VLDL2-apoB100 and triglyceride were not different between carriers 
and controls. In conclusion, the TM6SF2 E167K genetic variant was linked to a specific reduction 
in hepatic secretion of large triglyceride-rich VLDL1. The impaired secretion of VLDL1 explains the 
reduced plasma triglyceride concentration and provides a basis for understanding the lower risk of 
cardiovascular disease associated with the TM6SF2 E167K genetic variant.
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protein with 7–10 predicted transmembrane domains (9) that resides in the endoplasmic reticulum (ER) 
and the ER-Golgi intermediate compartment (ERGIC) (9).
In theory, the E167K variant could induce hepatic fat accumulation by increasing the inflow or syn-
thesis of  lipids in the liver (i.e., by stimulating hepatic lipid uptake or hepatic de novo lipogenesis [DNL]), 
or by blocking lipid catabolism or outflow (i.e., by reducing hepatic β-oxidation or very low-density lipo-
protein [VLDL] secretion) (10–16). Of  these potential mechanisms, attention has focused most on VLDL 
metabolism. In an in vitro model TM6SF2 E167K was associated with reduced hepatic secretion of  VLDL 
triglyceride (TG) (9, 17), and inhibition of  Tm6sf2 expression in mice resulted in increased lipid drop-
let TG content and impaired secretion of  VLDL-TG (9, 17, 18). Interestingly, Smagris et al. observed 
in Tm6sf2-deficient mice no decrease in the number of  VLDL particles secreted but a smaller diameter 
for VLDL (18). These observations raise the possibility that TM6SF2 may regulate hepatic lipidation of  
nascent VLDL prior to its secretion into the bloodstream (18). This mechanism would also explain why 
the TM6SF2 E167K variant associates with lower plasma cholesterol and TG levels in population studies 
(7, 19). However, other findings in animal and in vitro models complicate the picture and argue against this 
hypothesis; hepatic overexpression of  mouse Tm6sf2 leads to decreased plasma TG (17), while transient 
overexpression of  human TM6SF2 in mice results in increased plasma lipid levels (20). Further, expression 
of  TM6SF2 E167K in vitro has been shown to upregulate genes involved in cholesterol biosynthesis and 
DNL but to reduce apolipoprotein B100 (apoB100) secretion (21). These conflicting findings — especially 
the fact that Tm6sf2 overexpression appears to lead to the same phenotype as Tm6sf2 deficiency — question 
how well results from mouse models translate into human physiology in this instance and demonstrate the 
clear need for clinical metabolic studies to clarify the issue.
Investigations of  hepatic lipid metabolism in humans have reported that the TM6SF2 E167K genetic 
variant causes relative phosphatidylcholine (PC) deficiency due to impaired synthesis of  this lipid from 
polyunsaturated fatty acids (22). Carriers of  the genetic variant have also been shown to have increased 
cholesteryl esters in the liver and an altered profile of  circulating TG species (23). A fundamental gap in 
our understanding is the impact of  TM6SF2 on plasma lipid and lipoprotein metabolism in humans and its 
consequences for risk of  cardiovascular disease. Of  particular importance is the effect of  the E167K variant 
on the rates of  synthesis, secretion, and lipolysis of  VLDL because these lipoproteins give rise through 
delipidation and remodeling to the cholesterol-rich lipoprotein species — remnants and LDL — that are 
implicated in atherogenesis. To address this, we performed for the first time to our knowledge detailed 
kinetic studies of  apoB100 and TG metabolism in VLDL in subjects homozygous for TM6SF2 E167K to 
test the hypothesis that the genetic variant affects hepatic VLDL secretion.
Results
Phenotypic characterization of  study subjects. We examined homozygote TM6SF2 E167K carriers (n = 10) and con-
trol subjects (n = 10). The 2 groups were matched for BMI, waist circumference, and indices of glucose homeo-
stasis; measures of visceral (VAT) and abdominal subcutaneous (SAT) adipose tissue also did not differ signifi-
cantly between the groups (P = 0.35 for both). As expected, the TM6SF2 E167K carriers had more than 2-fold 
higher liver fat content than noncarriers (mean of 8.4% ± 6.1 vs. 4.0% ± 5.2, respectively, P = 0.023) (Table 1).
Plasma lipoprotein levels and VLDL composition. Both total plasma apoB (81 ± 19 vs. 106 ± 19 mg/dL; P = 
0.003) and plasma TG (1.0 ± 0.5 vs. 1.4 ± 0.3 mmol/L; P = 0.011) were significantly lower in homozygote 
TM6SF2 carriers compared with controls (Table 1). The reduction in plasma TG was mainly attributable to 
a 50% reduction of  the amount of  this lipid in VLDL1 (Table 1).
Lipidomic analysis of  isolated VLDL1 and VLDL2 showed that the composition of  these lipoproteins 
with respect to major lipid classes did not differ between the 2 subject groups (Table 2). Closer investiga-
tion of  individual lipid species did, however, reveal differences between the 2 genotypes. In both VLDL1 
and VLDL2 TG, the relative abundance of  unsaturated fatty acids in the TM6SF2 carriers decreased with 
increased number of  double bonds (Figure 1).
VLDL kinetics. To test the hypothesis that the TM6SF2 E167K genetic variant has a specific effect 
on hepatic VLDL secretion, we measured apoB100 and TG kinetics in the 2 major VLDL subfractions 
— large TG-rich VLDL1 and smaller, less TG-rich VLDL2. Results showed that production of  VLDL1-
apoB100, which is reflective of  the number of  VLDL1 particles secreted per day, was markedly reduced 
in homozygote TM6SF2 E167K carriers compared with controls (435 ± 200 vs. 788 ± 210 mg/d, P = 
0.003) (Table 3). Likewise, production of  VLDL1-TG was 35% lower in the former compared with the 
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latter group (21,307 ± 10,831 vs. 32,774 ± 13,055 mg/d, P = 0.043). In contrast, the direct produc-
tion rates for VLDL2-apoB100 and -TG were not different between carriers and noncarriers (Table 3). 
Fractional catabolic rates (FCRs) for VLDL1 and VLDL2-apoB100 and -TG did not differ significant-
ly between the groups (Table 3). There were no significant differences in hepatic DNL measured in 
VLDL1 or plasma β-hydroxybutyrate levels (i.e., a marker of  hepatic β-oxidation) between the 2 groups 
of  study subjects (Table 1).
Because plasma apoC-III levels are strong predictors of  VLDL1-TG FCR (24) and there was a 
tendency to lower levels of  this apoprotein in the TM6SF2 homozygotes, we explored the association 
of  plasma apoC-III levels with VLDL1-TG FCR in the 2 subject groups and found that the difference 
in apoC-III plasma levels did not correlate with the difference in VLDL1-FCR (r = –0.21, P = 0.39).
Discussion
The aim of  the present study was to elucidate further the phenotype associated with the genetic variant 
TM6SF2 E167K, in particular how it affects hepatic VLDL secretion, and by extrapolation risk of  ath-
erosclerotic cardiovascular disease. Our results show clearly that in subjects homozygous for this vari-
ant, there is a specific impact on the synthesis and secretion of  large TG-rich VLDL1 but no effect on 
the direct secretion of  the smaller, less TG-rich VLDL2. This finding is informative since we know from 
previous studies that production of  these 2 VLDL subfractions is regulated independently (25). There 
was no significant influence of  the TM6SF2 E167K variant on the lipolysis or clearance rates of  either 
Table 1. Baseline characteristics of study subjects
CONTROL TM6SF2 Fold P value
Age (y) 54.9 ± 9 58.4 ± 12.5 1.06 0.21
Syst. BP (mmHg) 134 ± 11 138 ± 16 1.02 0.68
Diast. BP (mmHg) 83.1 ± 5.9 85 ± 6.4 1.02 0.76
BMI (kg/m2) 27.6 ± 3.1 27.5 ± 2.7 1.00 1.00
Body weight (kg) 83.9 ± 10.2 77.9 ± 10.2 0.93 0.11
Waist (cm) 98.6 ± 8.5 99.8 ± 7.2 1.01 0.85
SAT area (cm2) 3324 ± 742 3642 ± 904 1.10 0.35
VAT area (cm2) 1898 ± 923 1431 ± 311 0.75 0.35
Liver fat (%) 4.0 ± 5.2 8.4 ± 6.1 2.10 0.023
Glucose (mmol/L) 5.4 ± 0.5 5.7 ± 0.4 1.06 0.24
Insulin (mU/L) 8.1 ± 6.2 11.3 ± 5.9 1.40 0.15
HOMA-IR 2.0 ± 1.5 2.9 ± 1.6 1.45 0.19
ALT (U/L) 28 ± 16 28 ± 10 0.99 0.57
ALP (U/L) 67 ± 10 65 ± 24 0.98 0.44
AST (U/L) 31 ± 9 27 ± 5 0.87 0.38
Total chol (mmol/L) 5.1 ± 0.5 4.8 ± 0.9 0.94 0.25
LDL-chol (mmol/L) 3.4 ± 0.5 3.0 ± 0.7 0.88 0.12
HDL-chol (mmol/L) 1.2 ± 0.4 1.6 ± 0.5 1.33 0.054
Fasting TG (mmol/L) 1.4 ± 0.3 1.0 ± 0.5 0.71 0.011
VLDL1-TG (mmol/L) 0.6 ± 0.3 0.3 ± 0.2 0.50 0.011
VLDL2-TG (mmol/L) 0.2 ±0.1 0.2 ± 0.1 1.00 0.089
ApoB (mg/dL) 106 ± 19 81 ± 19 0.76 0.003
VLDL1-apoB (mg/dL) 2.0 ± 1.0 1.0 ± 0.6 0.50 0.029
VLDL2-apoB (mg/dL) 3.0 ± 1.6 2.1 ± 1.1 0.70 0.22
ApoC-III (mg/dL) 12.1 ± 2.5 9.9 ± 1.9 0.82 0.064
FFA (μmol/L) 428 ± 149 534 ± 223 1.25 0.28
DNL in VLDL1 (%) 5.9 ± 5.1 8.6 ± 10.1 1.46 1.00
β-OH butyrate (mg/dL) 0.9 ± 0.6 1.2 ± 0.6 1.33 0.14
Fold difference is the ratio of means in the groups, >1 is higher in the TM6SF2 homozygote group. P values are from the Kruskal-Wallis test. Bold 
text indicates P < 0.05. Syst., systolic; diast., diastolic; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; HOMA-IR, Homeostatic 
Model Assessment of Insulin Resistance; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; FFA, free 
fatty acids; DNL, de novo lipogenesis; β-OH butyrate, β-hydroxy butyrate.
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VLDL subfraction. The decrease in VLDL1 production is the likely proximal cause of  the reduction in 
plasma apoB, although it should be noted that the decrease in VLDL1 apoB concentration in TM6SF2 
E167K homozygotes was insufficient to account for the much larger decrease in apoB overall. It is likely 
that a consequent fall in the levels of  the delipidation products of  VLDL1 — remnants and LDL — 
contributed to the lower total apoB (25) and also to the reduced risk of  atherosclerotic cardiovascular 
disease associated with this genetic variant (20, 26).
Cell culture studies have revealed that the assembly of  VLDL in hepatocytes is a multistage process 
(27). In the first step, primordial pre-VLDL particles are formed in the ER. These then enter the secre-
tory pathway and are converted to VLDL2-sized particles by incremental addition of  TG in a stepwise 
lipidation process (28). The precursor VLDL2 particles either are released from the cell (and are detect-
ed as “direct” VLDL2 apoB secretion in Table 3) or undergo a further lipidation step to become large, 
TG-rich VLDL1, which are then secreted (28, 29). The conversion of  VLDL2-sized precursor particles 
to VLDL1 occurs in a smooth membrane compartment, likely the ERGIC (30). The process requires 
bulk addition of  TG because VLDL1 contains a mean of  43,154 molecules of  TG per particle (i.e., per 
apoB, Table 2) compared with the 11,180 per particle in VLDL2. Formation of  VLDL1 is believed to be 
mediated by fusion of  a lipid droplet formed in the smooth ER with the VLDL2-sized precursor (31).
Thus, assembly of  TG-rich VLDL1 is highly dependent on the availability of  TGs to form these 
smooth ER lipid droplets, which in turn requires a ready supply of  TG within the hepatocyte (32). This 
can come from DNL, fatty acid uptake from the circulation, or mobilization of  cytoplasmic lipid stores 
(macroscopic lipid droplets) (33). The last is a major source, and VLDL1 secretion is a way in which the 
liver can regulate the amount of  stored intracellular TG (33, 34). In most subject groups it is possible 
to observe an association between the amount of  TG in intracellular stores (liver fat) and the secretion 
rates of  VLDL1 apoB100 and TG (34). Inheritance of  the TM6SF2 E167K variant disrupts this relation-
ship; liver fat increases but VLDL1 secretion is reduced.
Given the information available from this and earlier studies, it is reasonable to postulate that 
TM6SF2 which is located in the ER/ERGIC region (and hence adjacent to the lipoprotein assembly 
and secretion pathway) may be critical for the formation of  lipid droplets that fuse with VLDL2-sized 
precursor particles to form VLDL1 or be required for the fusion process per se. The mechanism respon-
sible for the generation of  lipid droplets within the ER is not completely clear. It is known that enzymes 
capable of  synthesizing neutral lipids are present in this cellular location (35–37), and once formed, 
small primordial droplets increase in size as they pass through the smooth ER, either by individual 
Table 2. Lipid class composition (molecules per apoB) of VLDL1 and VLDL2 in control and homozygous 
TM6SF2 carriers
CONTROL TM6SF2 Fold P value
VLDL1
 CE 15,754 ± 6899 16,615 ± 4946 1.05 0.85
 LPC 621 ± 376 1007 ± 476 1.62 0.08
 PC 11,870 ± 5567 11,657 ± 3598 0.98 0.68
 PE 659 ± 209 891 ± 392 1.35 0.17
 SM 2155 ± 1024 2561 ± 949 1.19 0.31
 TG 43,154 ± 16,509 50,537 ± 14,357 1.17 0.11
VLDL2
 CE 13,207 ± 4479 10,410 ± 6274 0.79 0.28
 LPC 289 ± 170 359 ± 247 1.24 0.53
 PC 4795 ± 1634 3616 ± 2506 0.75 0.14
 PE 124 ± 53 131 ± 113 1.06 0.68
 SM 1888 ± 845 1329 ± 708 0.7 0.14
 TG 11,180 ± 4013 9078 ± 5425 0.81 0.35
Data are reported as mean ± SD and P values are calculated using the Kruskal-Wallis test. CE, cholesteryl esters; 
LPC, lysophosphatidylcholines; PC, phosphatidylcholines; PE, phosphatidylethanolamines; SM, sphingomyelins, 
TG, triglycerides.
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expansion or by fusion with other droplets (33, 36, 37). The availability of  phospholipids, especially 
PC, is considered an important factor in facilitating the increase in size of  lipid droplets (38). Krahmer 
et al. demonstrated that expanding lipid droplets recruit CTP:phosphocholine cytidylyltransferase, the 
rate-limiting enzyme for PC synthesis, and that this enzyme is activated when it binds to the surface 
of  the droplets (38). Luukkonen et al. demonstrated that the TM6SF2 E167K genetic variant leads to 
altered hepatic lipid metabolism, resulting in relative PC deficiency due to impaired synthesis of  this 
lipid from polyunsaturated fatty acids (22). In accord with this finding, we observed significant decrease 
in the relative abundance of  longer and more unsaturated fatty acids in VLDL1 and VLDL2 TGs in 
homozygous carriers of  the TM6SF2 E167K genetic variant. Thus, it is possible that PC deficiency due 
to inheritance of  the TM6SF2 E167K variant leads to an assembly defect and failure to synthesize and 
secrete large TG-rich VLDL particles from the liver. However, the observation about fatty acid length 
and saturation was observed in both large TG-rich VLDL1 and smaller VLDL2 fractions. This finding 
argues against a specific effect on the assembly of  large VLDL1 particles.
It is also possible that the impact of  the genetic variant is secondary and caused by other genes that 
are coexpressing with TM6SF2 as proposed by Luukkonen et al. (22). This action has been suggested 
to explain the reduced hepatic expression of  apoC-III in subjects with the TM6SF2 E167K variant 
(22). ApoC-III has a number of  roles in VLDL metabolism. Pertinent to the present discussion is the 
proposal that this apolipoprotein may exert its effects on lipid substrate utilization for the second-step 
VLDL assembly process (39). Very recently, Li et al. reported that TM6SF2 stabilizes apoB by inter-
acting with ER lipid raft protein 1 and 2, which mediates the ER-associated degradation of  inositol 
1,4,5-trisphosphate receptors (40). However, the relevance of  these findings for human pathophysi-
ology is still unclear, and it is not evident how defective apoB stabilization would specifically impair 
hepatic VLDL1 secretion.
In conclusion, here we demonstrate that the TM6SF2 E167K genetic variant is linked to a specific 
reduction in hepatic secretion of  VLDL1. The proposed underlying mechanism is a relative failure 
to secrete large, TG-rich lipoproteins, and the inability to export lipid efficiently through the VLDL 
pathway is a satisfactory explanation for the accumulation of  liver fat. The 35% reduction in flow of  
apoB down the delipidation cascade will have predictable consequences for the products of  lipolysis of  
VLDL1 — remnant VLDL particles and LDL — which are implicated as causal factors in atherosclero-
sis (25). These metabolic perturbations explain the reduced plasma TG concentrations (7, 26, 41), and 
lower risk of  cardiovascular disease (20, 26) associated with the TM6SF2 E167K genetic variant.
Figure 1. Decrease in the relative abundance (analyzed as mol%) of longer and more unsaturated fatty acids in 
VLDL1 and VLDL2 TGs in homozygous carriers of the TM6SF2 E167K genetic variant. Lipids were extracted from 
VLDL1 and VLDL2, and the number of double bonds in fatty acids (i.e., degree of unsaturation) in TGs containing 
48 to 58 carbon molecules was determined. The colors indicate the ratio of the individual lipid species in carriers 
of the TM6SF2 E167K genetic variant (n = 10) versus controls (n = 10). A linear mixed model with number of double 
bonds as fixed effect and subject as random effect was used to test for a linear effect of the number of double 
bonds, within fixed chain lengths. Data were normalized to mean of control group; P values correspond to tests of 
the linear effect of double bonds differing from 0. *P < 0.05.
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Methods
Subjects. A group of  20 subjects, recruited on the basis of  their TM6SF2 E167K and PNPLA3 I143M geno-
types, participated in this study. Twelve subjects, identified from the THL Biobank (a country-wide biobank 
that collects and stores research samples from all over Finland, https://thl.fi/en/web/thl-biobank/about-
thl-biobank), had participated in earlier studies where exome sequencing or genotyping and imputation had 
been performed to explore genes involved in lipid metabolism. The remaining 8 subjects came from previ-
ously examined kinetic study cohorts (24, 42, 43). All had given oral consent that allowed them to be invit-
ed to further studies focused on lipid metabolism. Two groups were included in this study: 10 homozygote 
carriers for TM6SF2 E167K (9 men and 1 woman) and 10 control subjects (9 men and 1 woman), matched 
for degree of  obesity and glycemic status, who were not carriers of  TM6SF2 E167K and also were not 
homozygous for PNPLA3 I143M (Table 1). Inclusion criteria were age 18–70 years, nonsmoking status, and 
BMI < 33 kg/m2. Exclusion criteria included a history of  cardiovascular or other severe disease, any con-
dition affecting lipid levels, abnormalities in thyroid or kidney function, liver disease other than NAFLD, 
abnormal blood count, glycated hemoglobin (HbA1c) > 42 mmol/mol, LDL-cholesterol > 4.5 mmol/L, 
plasma TG > 2.5 mmol/L, uncontrolled hypertension (>160 mmHg systolic and /or >105 mmHg diastolic 
blood pressure), use of  thiazide diuretics (>25 mg/d), use of  medications affecting lipid or glucose metab-
olism, or high alcohol consumption (>30 g/d for men and >20 g for women). The participants were asked 
to abstain from alcohol and strenuous physical exercise during leisure time before metabolic investigations.
Study design. The kinetic studies were performed as described previously (24, 44). On the evening before the 
VLDL apoB100/TG kinetic study, 2H2O (2 g/kg) was given between 1800 and 2200 hours to give an assessment 
of the degree of the contribution of hepatic DNL to VLDL1 TGs (see refs. 45, 46). The subjects came back at 
7:30 am to the research unit of the Helsinki University Hospital after a 12-hour overnight fast. An indwelling 
cannula was inserted into an antecubital vein for blood sampling, and a second cannula was inserted into the 
opposite antecubital vein. The subjects received a bolus injection of [2H5]-glycerol (500 mg) and [
2H3]-leucine (7 
mg/kg). Blood samples were drawn before tracer injection and at frequent intervals thereafter (24, 44).
Lipoprotein isolation. VLDL1 and VLDL2 were separated from plasma as described previously (44). 
ApoB100 was obtained from the 2 VLDL subfractions and hydrolyzed, derivatized, and subjected to gas chro-
matography mass spectrometry to measure tracer leucine enrichment (44). Likewise, TG was extracted from 
the VLDL fractions and the tracer glycerol enrichment determined (44). The particle composition and apoB 
mass of  VLDL1 and VLDL2 were determined before and at 4 and 8 hours after tracer injection. The subjects 
continued to fast until 5 pm, when the last blood sample was taken and they were served a standard dinner.
Biochemical analyses. Fasting TG and cholesterol concentrations in total plasma and in the VLDL1 and 
VLDL2 fractions, and HDL-cholesterol and LDL-cholesterol, were analyzed by automated enzymatic meth-
ods using the Konelab 60i analyzer (Thermo Fisher Scientific). Concentrations of  glucose (Gluco-quant, 
Roche Diagnostics) and insulin (electrochemiluminescence with Roche sandwich immunoassay using 
Table 3. Absolute production rates and fraction clearance rates of VLDL1 and VLDL2 apoB and TGs
CONTROL TM6SF2 Fold P value
ApoB
 Total VLDL production (mg/d) 1046 ± 218 731 ± 271 0.70 0.015
 VLDL1 production (mg/d) 788 ± 210 435 ± 200 0.55 0.003
 VLDL1 FCR (pools/d) 13.8 ± 8.2 18.6 ± 8.3 1.34 0.32
 VLDL2 production (mg/d) 258 ± 66 296 ± 130 1.15 0.32
 VLDL2 FCR (pools/d) 6.8 ± 2.3 8.2 ± 4.1 1.21 0.58
TGs
 Total VLDL production (mg/d) 36,622 ± 12,398 25,561 ± 11,687 0.70 0.052
 VLDL1 production (mg/d) 32,774 ± 13,055 21,307 ± 10,831 0.65 0.043
 VLDL1 FCR (pools/d) 21.5 ± 15.2 33.9 ± 18.2 1.56 0.19
 VLDL2 production (mg/d) 3848 ± 1272 4254 ± 1984 1.11 0.74
 VLDL2 FCR (pools/d) 19.3 ± 14.1 17.0 ± 5.4 0.88 0.74
Fold difference is the ratio of means in the groups, >1 is higher in the TM6SF2 homozygote group. P values are from the Kruskal-Wallis test. Bold text 
indicates P < 0.05. Data are reported as mean ± SD. FCR, fractional clearance rate.
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Cobas autoanalyzer) were measured in fasting blood samples and HOMA-IR was calculated (47). Plas-
ma levels of  apoC-III were measured immune-turbidometrically (Kamiya Biochemical Company) and 
β-hydroxybutyrate concentrations by using a β-hydroxybutyrate FS kit (Diagnostic Systems) on a Konelab 
60i analyzer (Thermo Fisher Scientific). Plasma fatty acids were analyzed using an automatic enzymatic 
colorimetric method (Wako Chemicals).
Lipidomics. Lipid extraction of  50 μL of  each VLDL fraction was performed using the BUME method 
(48). TGs were quantified by direct infusion (shotgun) analysis on a QTRAP 5500 mass spectrometer (SCI-
EX) equipped with a robotic nanoflow ion source, TriVersa NanoMate (Advion BioSciences). The analysis 
was performed in positive ion mode by neutral loss detection of  10 common acyl fragments formed during 
collision-induced dissociation according to previous work (49). Glyceryl-d5-hexadecanoate (CDN Isotopes) 
was added during the extraction and used for quantification.
Imaging. Liver fat content was measured using proton magnetic spectroscopy (1.5 T whole-body device) 
(34), and subcutaneous and visceral fat were measured by magnetic resonance imaging (50). All imaging 
analyses were performed by a single person. Subjects were advised to fast for 4 hours before scans were taken.
Genotyping. The genotypes of  participants were confirmed upon recruitment to the present study. DNA 
was extracted from blood using DNeasy Blood & Tissue Kit (Qiagen) and used to determine TM6SF2 
rs58542926 (E167K) and PNPLA3 rs738409 (I148M) status by TaqMan assays (Life Technologies, Thermo 
Fisher Scientific) using CFX384 Real Time PCR detection system (Bio-Rad Laboratories). Data analysis 
was performed using Bio-Rad CFX manager software.
Modeling. The multicompartmental model used to analyze simultaneously VLDL apoB100 and TG 
kinetics was constructed using SAAM II (The Epsilon Group) (51). Inputs to the model were (a) inject-
ed amounts of  [2H3] leucine and [
2H5] glycerol, (b) apoB100 and TG pool sizes in VLDL1 and VLDL2, 
(c) enrichment curve of  plasma leucine, (d) enrichment of  deuterated leucine in in VLDL1- and VLDL2-
apoB100, and (e) enrichment of  deuterated glycerol in VLDL1- and VLDL2-TG (44). Outputs were produc-
tion (in mg/d) and fractional clearance rates (in pools/d) for apoB100 and TG for each subfraction and the 
transfer rates from VLDL1 to VLDL2.
Statistics. Statistical calculations were performed using R (version 3.6.3). Data are reported as mean ± 
SD, and P values were calculated using the Kruskal-Wallis test. Correlation coefficients refer to the Spear-
man’s rank correlation coefficient. Trend analyses for lipidomics data were performed using linear mixed 
models with number of  double bonds as fixed effect and subject as random effect. Data were normalized to 
mean of  control group; P values correspond to tests of  the linear effect of  double bonds differing from 0. P 
< 0.05 was considered statistically significant.
Study approval. The study protocol was approved by the Ethics Committee of  Helsinki University Cen-
tral Hospital, Helsinki, Finland. ClinicalTrials.gov Identifier: NCT04209816. The study was performed in 
accordance with the Declaration of  Helsinki and the European Medicines Agency Note for guidance on 
good clinical practice. All study participants signed a written informed consent form before any study pro-
cedures were initiated.
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